✉news BusinessLabor first seen 9 h ago, last 2 h ago, peak #22
Novartis signs up to $7.8 billion mRNA deal with China's Abogen
Original: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Swiss drugmaker Novartis has agreed to a licensing deal worth up to $7.8 billion with China's Abogen Biosciences to develop mRNA-based therapies. The agreement gives Novartis access to Abogen's mRNA technology, highlighting growing Western pharmaceutical interest in Chinese biotech assets and keeping momentum behind mRNA platforms beyond vaccines.
Why now: The scale of the deal and Big Pharma's push into Chinese biotech are drawing attention.
Rank over time, top of the chart is #1. 6 snapshots from 9 h ago to 2 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/728004